Nurofen could face world of pain for misleading customers
IF YOU ever reached out for a brightly coloured packet of Nurofen while suffering a migraine, or period pain, you might have been lied to.
And now Nurofen faces a major class action in the Federal Court.
The company had sold a variety of Nurofen types that apparently targeted specific types of pain. The range include Nurofen tablets specifically aimed at period pain, back pain, migraines or tension headaches.
Each of the products all had the same amount of the active ingredient -- 342mg of ibuprofen lysine.
If the class action from Bannister Law is successful, it would force Reckitt Benckiser Australia to refund the purchase price for every box of pain tablets in the company's "specific pain range" sold between January 2011 and December 2015.
According to Bannister Law, consumers would expect the produce focuses on a particular type of pain and not others.
"No product in the Nurofen Specific Pain range is any more or less ffective than the others in treating any of the symptoms shown on the packaging," Bannister Law wrote in a statement.
After an ACCC investigation found Nurofen's products to have likely misled customers late last year, company spokeswoman Montse Pena said the goal of its products was to "help consumers navigate their pain options".
"Nurofen did not set out to mislead consumers. Nurofen has co-operated with the ACCC in relation to these proceedings and will fully comply with the court order," Ms Pena said after the ruling.